` 4568 (Daiichi Sankyo Co Ltd) vs Nikkei 225 Comparison - Alpha Spread

4568
vs
Nikkei 225

Over the past 12 months, has underperformed Nikkei 225, delivering a return of -31% compared to the Nikkei 225's 6% drop.

Stocks Performance
4568 vs Nikkei 225

Loading
4568
Nikkei 225
Add Stock

Performance Gap
4568 vs Nikkei 225

Sign Up to see
Performance Gap
Sign In
Sign Up

Performance By Year
4568 vs Nikkei 225

Loading
4568
Nikkei 225
Add Stock

Competitors Performance
Daiichi Sankyo Co Ltd vs Peers

Nikkei 225
4568
LLY
JNJ
NOVO B
ROG
Add Stock

Daiichi Sankyo Co Ltd
Glance View

Economic Moat
Narrow
Market Cap
6.2T JPY
Industry
Pharmaceuticals

Daiichi Sankyo Co., Ltd., a cornerstone of Japan's pharmaceutical industry, embarked on its journey in 2005 from the merger of two storied companies, Daiichi Pharmaceutical and Sankyo Co., both with roots stretching back to the early 20th century. They combined their rich histories and expertise to form a global powerhouse in healthcare. Daiichi Sankyo has since developed a compelling narrative in creating innovative pharmaceuticals, with a particular focus on oncology, managing cardiovascular risks, and tackling inflammatory diseases. This dedication is reflected in its flagship product, Enhertu (trastuzumab deruxtecan), a cutting-edge therapy in the field of oncology that has gained considerable global traction and approval for treating HER2-positive cancers. Constantly investing in research and development, the company aims to enhance its portfolio through innovative drugs that fulfill unmet medical needs, thereby driving sustainable growth. The financial engine propelling Daiichi Sankyo forward is fueled by its robust product pipeline and strategic partnerships, such as its collaboration with AstraZeneca. These alliances not only bolster its research capabilities but also extend its market reach, especially in regions where regulatory landscapes can be intricate. While its revenue streams are primarily generated from pharmaceuticals, the company also invests in over-the-counter medications and vaccines, contributing to a diversified revenue base. Daiichi Sankyo’s strategy of maintaining a balanced portfolio, combined with its strategic commitment to pioneering treatments in oncology, aligns with its broader vision of being a leader in the global pharmaceutical arena, translating their scientific discoveries into tangible health solutions worldwide.

Daiichi Sankyo Co Ltd Intrinsic Value
HIDDEN
Show
Back to Top